Following Off Script: A Pharma Manufacturing Podcast's news feed is very easy. Subscribe using the "follow" button on the top right and if you want to, choose the updates by topic or tag.
We will deliver them to your inbox, your phone, or you can use follow.it like your own online RSS reader. You can unsubscribe whenever you want with one click.
Keep up to date with Off Script: A Pharma Manufacturing Podcast!
Off Script: A Pharma Manufacturing Podcast: Off Script: A Pharma Manufacturing Podcast
Is this your feed? Claim it!
In this episode of Off Script, we continue our conversation with John Murphy III, president and CEO of the Association for Accessible Medicines, to dig deeper into the vulnerabilities and structural challenges shaping U.S. generic and biosimilar drug production.
Murphy examines the most fragile links in the supply chain — from the lack of domestic API production to key...
In this episode of Off Script, we spoke with John Murphy III, president and CEO of the Association for Accessible Medicines, about the forces shaping the future of U.S. generic and biosimilar manufacturing.
Murphy provides a high-level look at the pivotal shifts defining the generic drug landscape and breaks down the economic realities driving drug shortages, ...
While the cell and gene therapy space represents one of the most exciting therapeutic frontiers in modern biopharma by offering highly personalized, transformative treatments, the sector still faces significant hurdles before it can achieve widespread commercialization. From steep manufacturing costs and a lack of standardization to persistent inefficiencies in scaling produc...
In part two of our conversation with Brian Scanlan, Advisor of Life Sciences at Edgewater Capital Partners, we explore how today’s CDMO funding trends are shaping the next phase of growth and specialization across the contract research and manufacturing ecosystem.
Brian shares his perspective on:
As we near the end of 2025, the CDMO industry finds itself at a pivotal financial and strategic juncture — shaped by constrained funding, shifting demand, and renewed investor scrutiny.
In this episode of Off Script, we speak with Brian Scanlan, Advisor of Life Sciences at Edgewater Capital Partners, to examine how the year’s market and investment trends...
